IL2 and multiple sclerosis: The immunomodulatory effects of NTZ on cytokine concentrations are relevant because individual cytokine modulators are frequently used for severe inflammatory diseases, such as tocilizumab (IL-6 inhibitor) in rheumatoid arthritis [59], daclizumab (IL-2 inhibitor) in multiple sclerosis [60], and anakinra (IL-1 inhibitor) in other autoimmune diseases [61].